Kronos Bio to Cut 83% Of Workforce, Names Interim CEO

Dow Jones
2024-11-27

By Ben Glickman

 

Kronos Bio said it would cut about 83% of its workforce by the end of the year and named a new interim chief executive, as the company continues to explore strategic options.

The San Mateo, Calif., biotechnology company said Wednesday that Deborah Knobelman had been appointed president and interim CEO, effective Dec. 3.

CEO Norbert Bischofberger, who has been with the company since 2018, will step down while remaining on the board of directors.

Kronos said the workforce reduction was part of its previously announced plan to cut costs and is expected to be completed by the end of the year. The company is exploring options, including a possible business combination or divestiture of its assets.

The cuts follow a 21% workforce reduction which was announced in March. Kronos expects to incur a charge of about $3.7 million related to the reduction.

 

Write to Ben Glickman at ben.glickman@wsj.com

 

(END) Dow Jones Newswires

November 27, 2024 07:47 ET (12:47 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10